Peer reviewed publications, last 20 years, out of 634 papers:

1. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones W, Haywood J, Maxey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG, Wright JT Jr. Management of high blood pressure in African Americans: The hypertension in African Americans Working Group. Arch Int Med 2003;163:525-541.
2. Fritsch Neves M, Virdis A, Schiffrin EL. Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism. J Hypertens 2003; 21:189-198.
3. Iglarz M, Touyz RM, Amiri F, Lavoie M-F, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor- and – activators on vascular remodeling in endothelin-dependent hypertension. Arterioscl Thromb Vasc Biol 2003;23:45-51.
4. Fritsch Neves M, Virdis A, Schiffrin EL. Review: Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 2003; 5:59-65.
5. Schiffrin EL. Review : Effect of antihypertensive treatment on small artery remodeling in hypertension. Proceedings of a Montreal Satellite Symposium of the XVIIth World Congress of the International Society for Heart Research in the Cardiovascular System and Inflammatory Mediators, Montréal, July 12-14, 2001, Can J Physiol Pharmacol, 2003;81:168-176
6. Touyz RM, Cruzado M, Tabet F, Yao G, Salomon S, Schiffrin EL. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells – role of receptor tyrosine kinase transactivation. Proceedings of a Montreal Satellite Symposium of the XVIIth World Congress of the International Society for Heart Research in the Cardiovascular System and Inflammatory Mediators, Montréal, July 12-14, 2001, Can J Physiol Pharmacol 2003;81:159-167.
7. Virdis A and Schiffrin EL. Review: Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 2003;12(2):181-187.
8. Iglarz M, Schiffrin EL. Review: Role of endothelin-1 in hypertension. Curr Hypertens Rep 2003;5:144-148.
9. Schiffrin EL, Touyz RM. Editorial: Inflammation and vascular hypertrophy induced by angiotensin II: Role of NADPH oxidase-derived reactive oxygen species independently of blood pressure elevation? Arterioscler Thromb Vasc Biol 2003;23:707-709.
10. Touyz RM, Yao G and Schiffrin EL. c-Src induces phosphorylation and translocation of p47phox. Role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:981-987.
11. Schiffrin EL, Touyz RM. Editorial : Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol 2003;42(5):911-913.
12. Moreau P, Schiffrin EL. Review: Role of endothelins in animal models of hypertension. Can J Physiol Pharmacol 2003;81:511-521.
13. Touyz RM, Schiffrin EL. Review: Role of endothelin in human hypertension. Can J Physiol Pharmacol 2003;81:533-541.
14. Pu Q, Fritsch Neves M, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003;42:49-55.
15. Schiffrin EL, Amiri F, Benkirane K, Iglarz M and Diep QN. Review: Peroxisome proliferators-activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003;42:664-668.
16. Virdis A, Iglarz M, Fritsch Neves M, Amiri F, Touyz RM, Rozen R, Schiffrin EL. Effect of hyperhomocysteinemia and its association with hypertension on endothelial function and vascular structure in methylenetetrahydrofolate reductase-deficient mice. Arterioscl Thromb Vasc Biol 2003;23:1352-1357.
17. Javeshghani D, Touyz RM, Ram Sairam M, Virdis A, Fritsch Neves M, Schiffrin EL. Attenuated responses to angiotensin II in follitropin receptor knockout mice, a model of menopause-associated hypertension. Hypertension 2003;42:761-767.
18. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL. Peroxisome proliferator-activated receptor- and receptor– activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003;42 737-743.
19. Callera GE, Touyz RM, Teixeira SA, Muscara MN, Carvalho MH, Fortes ZB, Nigro D, Schiffrin EL, Tostes RC. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003;42(4):811-817.
20. Pu Q, Larouche I, Schiffrin EL. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats. Am J Hypertens 2003;16(11):931-937.
21. Schiffrin EL. Editorial: The angiotensin-endothelin relationship: does it play a role in cardiovascular and renal pathophysiology? J Hypertens 2003;21(12):2245-2247.
22. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 2003;30:860-866.
23. Ruilope LM, Segura J and Schiffrin EL. Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients? J Renin Angiotensin Aldosterone Syst 2003;4(2):74-79.
24. Savoia C and Schiffrin EL. Review: Natriuretic peptides as a diagnostic and therapeutic tool in cardiovascular disease. High Blood Press Cardiovasc Prev 2003;10(2):105-110.
25. Tabet F, Savoia C, Schiffrin EL. Touyz RM. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004;44(2):200-208.
26. Hermann F, Ruschitzka FT, Schiffrin EL. Clinical Trials Report: The Sweet Secret of Dark Chocolate, CHARM-Overall Programme, CHARM-Added Trial, CHARM-Alternative Trial, CHARM-Preserved Trial. Curr Hypertens Rep 2004;6(1):45-50.
27. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPAR activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004;36(2):295-304.
28. Endemann DH, Schiffrin EL. Review : Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Curr Hypertens Rep 2004;6(2):85-89.
29. Elijovich F, Laffer CL, Schiffrin EL, Gavras H, Amador E. Endothelin-aldosterone interaction and proteinuria in low-renin hypertension. J Hypertens 2004;22(3):573-582.
30. Virdis A, Fritsch Neves M, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 2004;22(3):535-542.
31. Endemann DH, Pu Q, De Ciuceis C, Savoia C, Virdis A, Neves MF, Touyz RM, Schiffrin EL. Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment. Hypertension 2004;43(2):399-404.
32. El Mabrouk M, Diep QN, Benkirane K, Touyz RM, Schiffrin EL. SAM68: a downstream target of angiotensin II signaling in vascular smooth muscle cells in genetic hypertension Am J Physiol Heart Circ Physiol 2004;286(5):H1954-H1962.
33. Callera GE, Montezano AC, Touyz RM, Zorn, TM, Carvalho MH, Fortes ZB, Nigro D, Schiffrin EL, Tostes RC. ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats. Hypertension 2004;43(4):872-879.
34. Neves MF, Endemann D, Amiri F, Virdis A, Pu Q, Rozen R, Schiffrin EL. Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II. J Hypertens 2004;22(5):959-966.
35. Schiffrin EL. Editorial: The many targets of aldosterone. Hypertension 2004;43(5):938-940.
36. Touyz RM, Yao G, Viel E, Amiri F and Schiffrin EL. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 2004;22(6):1141-1149.
37. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. Am J Hypertens 2004;17(7):597-603.
38. Schiffrin EL and Touyz RM. Medical Editorial: From bedside to bench to bedside: Role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004;287(2):H435-H446.
39. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Eplerenone prevents salt-induced vascular remodelling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004;43(6):1252-1257.
40. Touyz RM, Schiffrin EL. Review: Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004;122(4):339-352.
41. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL and Schiffrin EL. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004;110(15):2233-2240.
42. Endemann D, Schiffrin EL. Review: Endothelial Dysfunction. J Am Soc Nephrol 2004;15(8):1983-1992.
43. Schiffrin EL. Review: Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 2004;17(12):1192-1200.
44. Schiffrin EL. Review: Vascular stiffening and arterial compliance: implications for systolic blood pressure. Am J Hypertens 2004;17(12):39S-48S.
45. Diep QN, Amiri F, Benkirane K, Paradis P and Schiffrin EL. Long-term effects of PPAR activator pioglitazone on cardiac hypertrophy and inflammation in SHRSP. Can J Physiol Pharmacol. 2004;82(11):976-985.
46. Hemmelgarn BR, Zarnke KB, Campbell NR, Feldman RD, McKay DW, McAlister FA, Khan N, Schiffrin EL, Myers MG, Bolli P, Honos G, Lebel M, Levine M, Padwal R; Canadian Hypertension Education Program, Evidence-Based Recommendations Task Force. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I-Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2004;20(1):31-40.
47. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ; Working Group on endothelin and Endothelial Factors of the European Society of Hypertension. Review: Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds. A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23(1):7-17.
48. Cruzado MC, Risler NR, Miatello RM, Yao G, Schiffrin EL and Touyz RM. Vascular smooth muscle cell NAD(P)H oxidase activity during the development of hypertension: Effect of angiotensin II and role of insulinlike growth factor-1 receptor transactivation. Am J Hypertens 2005;18(1):81-87.
49. Schiffrin EL. Review: Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2005;288(3):H1037-H1043.
50. Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 2005;23(2):401-409.
51. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S and Schiffrin EL. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005;45(4):773-779.
52. Touyz RM, Yao, G, Quinn MT, Pagano PJ, Schiffrin EL. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 2005;25(3):512-518.
53. Schiffrin EL, Touyz RM. Editorial: Calcium, Magnesium, and Oxidative Stress in Hyperaldosteronism. Circulation 2005;111(7):830-831.
54. Touyz RM, Yao, G and Schiffrin EL. Role of the actin cytoskeleton in angiotensin II signaling in human vascular smooth muscle cells. Can J Physiol Pharmacol 2005;83:91-97.
55. Savoia C, Tabet F, Yao G, Schiffrin EL, Touyz RM. Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells – role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 2005;23:1037-1045.
56. Schiffrin EL. Invited Review. Vascular endothelin in hypertension. Vasc Pharmacol 2005;43:19-29.
57. Hemmelgarn BR, McAlister FA, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin EL, Grover S, Honos G, Lebel M, Mann K, Wilson T, Penner B, Tremblay G, Tobe SW, Feldman RD. Canadian Hypertension Education Program, The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2005;21(8):645-656.
58. Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, Leiter LA, Lebel M, Herbert C, Schiffrin EL, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, deChamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Campbell NRC, Arnold M. Moe G, Hill MD, Jones C, Larochelle P, Ogilvie RI, Tobe S, Houlden R, Burgess E, Feldman RD. Canadian Hypertension Education Program, The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II – Therapy. Can J Cardiol 2005;21(8):657-672.
59. Brassard P, Amiri F, Schiffrin EL. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 2005; 46:598-606.
60. Schiffrin EL. Editorial: More evidence of cardiorenal protective effects of peroxisome proliferators-activated receptor activation. Hypertension 2005;46:267-268.
61. Schiffrin EL. Editorial: BP lowering in PROGRESS and white matter hyperintensities: Should this progress matter to patients? Circulation 2005;112:1525-1526.
62. Yokohama H, Averill DB, Brosnihan KB, Smith RD, Schiffrin EL, Ferrario CM. Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens 2005;18:922-929.
63. Callera GE, Montezano ACI, Yogi A, Tostes RC, He Y, Schiffrin EL, Touyz RM. C-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005;46(2):1032-1038.
64. Tabet F, Schiffrin EL, Touyz RM. MAP kinase Activation by H2O2 is Mediated Through Tyrosine Kinase-dependent, PKC-independent Pathways in Vascular Smooth Muscle Cells – Upregulation in SHR. J Hypertens 2005;23:2005-2012.
65. Fritsch Neves M, Amiri F, Virdis A, Diep QN, Schiffrin EL. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol 2005:83:999-1006.
66. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscl Thromb Vasc Biol 2005; 25 2106-2113.
67. Brassard P, Amiri F, Thibault G, Schiffrin EL. Role of angiotensin type-1 and angiotensin type-2 receptors in the expression of vascular integrins in angiotensin II-infused rats. Hypertension 2006:47:122-127.
68. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL. PPAR- inhibits angiotensin II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol (Heart Circul Physiol) 2006;290:H390-H397.
69. Benkirane K, Viel EC, Amiri F, Schiffrin EL. Peroxisome proliferator-activated receptor  regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 2006;47:102-108.
70. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 15:152-158.
71. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension Highlights. Hypertension 2006;47:312-318.
72. Savoia C, Touyz RM, He Y, Endemann D, Pu Q, Ko EA, De Ciuceis C, Schiffrin EL. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension. 2006;48:271-277.
73. White M, Ducharme A, Ibrahim R, Whittom L, Lavoie J, Guertin M-C, Racine N, He Y, Yao G, Rouleau JL, Schiffrin EL, Touyz RM. Systemic inflammation and oxidative stress are increased in patients with worsening congestive heart failure: Improvement after short-term inotropic support. Clin Sci 2006;110:384-389.
74. Touyz RM, Schiffrin EL. Peroxisome proliferator activated receptors in vascular biology – molecular mechanisms and clinical implications. Invited Review. Vascular Pharmacology. 2006;45:19-28.
75. Smith RD, Yokoyama H, Averill DB, Cooke L, Brosnihan KB, Schiffrin EL, Ferrario CM. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs. 2006;6:335-342.
76. Savoia C, Schiffrin EL. Inhibition of the renin angiotensin system: implications for the endothelium. Invited Review Curr Diabetes Reports 2006, 6:274-278.
77. Javeshghani D, Sairam MR, Fritsch Neves M, Schiffrin EL, Touyz RM. Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. J Hypertens. 2006;24:1365-1373.
78. Savoia C, Ebrahimian T, He Y, Gratton J-P, Schiffrin EL, Touyz RM. Angiotensin II/AT2 receptor-induced vasodilation in SHRSP involves nitric oxide and cGMP-dependent protein kinase. J Hypertens 2006;24:2417-2422.
79. Sampaio WO, Santos RAS, Faria-Silva R, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007;49:185-192.
80. Savoia C, Touyz RM, De Ciuceis C, Ko EA, Schiffrin EL. Angiotensin II type 2 receptor contributes to vascular responses in resistance arteries of type 2 diabetic hypertensive patients treated with angiotensin type 1 receptor blockers. Hypertension 2007;49:341-346.
81. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Invited review. Clin Sci 2007;112: 375-384.
82. Schiffrin EL. The vascular phenotypes in hypertension: relation to the natural history of hypertension. J Amer Soc Hypert 2007;1: 56-67.
83. Ko EA, Amiri F, Pandey NR, Touyz RM, Schiffrin EL. Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-csf deficient mice. Amer J Physiol (Heart Circul Physiol) 2007;292: H1789 - H1795.
84. Montezano AC, Amiri F, Tostes RC, Touyz RM, Schiffrin EL. Inhibitory effects of PPAR- on endothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats. J Amer Soc Hypert 2007;1:150-160.
85. De Ciuceis C, Amiri F, Iglarz M, Cohn JS, Touyz RM, Schiffrin EL. Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in Ang II-induced hypertension. Brit J Pharmacol 2007;151:45-53.
86. Savoia C, Schiffrin EL. Angiotensin Type 2 Receptors in the Cardiovascular System. High Blood Pressure & Cardiovascular Prevention 2007;14:63-68.
87. Pandey NR, Benkirane K, Amiri F, Schiffrin EL. Effects of PPAR-g Knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats. J Cardiovasc Pharmacol 2007;49:346-354.
88. Ebrahimian T, He Y, Schiffrin EL, Touyz RM. Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in Male and Female mice. J Hypertens 2007;25:1263-1272.
89. Schiffrin EL, Lipman M, Mann JFE. Chronic kidney disease: Effect on the cardiovascular system. Invited review. Circulation 2007;116:85-97.
90. Touyz RM, Savoia C, Endemann D, Pu Q, Ko EA, De Ciuceis C, Schiffrin EL. Systemic Inflammation is Increased in Hypertensive Type 2 Diabetic Patients: Improvement after Antihypertensive Therapy. J Amer Soc Hypert 2007;1:189-199.
91. Yogi A, Callera GE, Montezano ACI, Tostes RC, Schiffrin EL, Touyz RM. Endothelin-1, but not Ang II, activates MAP kinases through c-Src- independent, Ras-Raf-dependent, pathways in vascular smooth muscle cells. Atheroscl Thromb Vasc Biol 2007;27:1960-1967.
92. Leibovitz E, Schiffrin EL. PPAR activation: a new target for the treatment of hypertension. Invited review. J Cardiovasc Pharmacol 2007;50(2):120-125.
93. Leibovitz E, Schiffrin EL. Novel drugs targeting hypertension: Renin inhibitors and beyond. Invited review. J Cardiovasc Pharmacol 2007;50(1):3-8.
94. Javeshghani D, Sairam MR, Schiffrin EL, Touyz RM. Increased Blood Pressure, Vascular Inflammation and Endothelial Dysfunction in Androgen-Deficient Follitropin Receptor Knockout Male Mice. J Amer Soc Hypert 2007;1:353-361.
95. Savoia C, Schiffrin EL. Reduction of C-reactive protein and the use of anti-hypertensives. Invited review. Vascular Health and Risk Management. 2007;3:975-983.
96. Sampaio WO, de Castro CH, Santos R, Schiffrin EL, Touyz RM. Angiotensin-(1-7) counter-regulates angiotensin II signaling in human endothelial cells. Hypertension 2007; 50:1093-1098.
97. Schiffrin EL. Editorial commentary: Oxidative stress, NOS and SOD – a matter of imbalance underlies endothelial dysfunction in the human coronary circulation. Hypertension 2008;51:31-32.
98. Savoia C, Touyz RM, Amiri F, Schiffrin EL. The Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients. Hypertension 2008;51:432-439.
99. Bakris G, Hill M, Mancia G, Steyn K, Black HR, Pickering T, De Geest S , Ruilope L, Giles TD, Morgan T, Kjeldsen S, Schiffrin EL, Coenen A, Mulrow P, Loh A, Mensah G. Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. J Human Hypert. 2008;22:63-70.
100. Schiffrin EL. Editorial commentary: New twist to the role of the RAS in heart failure: Aldosterone upregulates renin-angiotensin system components in the brain. Hypertension 2008;51:622-623.
101. Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL. Effects of Combined AT1 Receptor Antagonist/NEP Inhibitor on Vascular Remodeling and Cardiac Fibrosis in SHRSP. J Hypertens. 2008;26:322-333.
102. Touyz RM, Schiffrin EL. Reactive oxygen species and hypertension – a complex association. Antioxidants & Redox Signaling. 2008;10: 1041-1044.
103. Marchesi C, Schiffrin EL. Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects. J Amer Soc Hypert. 2008; 2: 227-238.
104. Lemarié CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med. 2008;86:673–678.
105. Yokoyama H, Smith RD, Averill DB, Schiffrin EL, Ferrario CM. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J Am Soc Hypert. 2008; 2:165–172.
106. Amiri F, Paradis P, Reudelhuber TL, Schiffrin EL. Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. J Hypertens. 2008; 26:1102-1109.
107. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci (TIPS) 2008;29:367-374.
108. Tabet F, Schiffrin EL, Callera GE, He Y, Yao G, Ostman A, Kappert K, Tonks NK, Touyz RM. Redox-Sensitive Signaling by Angiotensin II Involves Oxidative Inactivation and Blunted Phosphorylation of Protein Tyrosine Phosphatase SHP-2 in Vascular Smooth Muscle Cells From SHR. Circ Res. 2008;103:149-158.
109. Viel EC, Benkirane K, Javeshghani D, Touyz RM, Schiffrin EL. Xanthine Oxidase and Mitochondria Contribute to Vascular Superoxide Anion Generation in DOCA-Salt Hypertensive Rats. Amer J Physiol (Heart Circ Physiol). 2008;295: H281-H288.
110. Schiffrin EL. The flame that lights the fire: Oxidative stress, inflammation and renal damage in Ang II-induced hypertension. Editorial. Hypertension. 2008; 52;205-206.
111. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, Schiffrin EL, Touyz RM. Cross-talk between Aldosterone and Angiotensin II Signaling Promotes Vascular Smooth Muscle Cell Migration Through c-Src-dependent Redox-sensitive RhoA Pathways. Arterioscl Thromb Vasc Biol. 2008;28:1511-1518.
112. Mann JFE, Hilgers KF, Veelken R, Schiffrin EL. Chronische Nierenerkrankungen und kardiovaskuläres System (Chronic kidney disease and the cardiovascular system). Internist. 2008;(49)4:413-413.
113. Levy B, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar M, Struijker-Boudier H. Impaired tissue perfusion: a pathology common to hypertension, obesity and diabetes. Circulation. 2008;118:968-976.
114. Dhaun N, Goddard J, Kohan D, Pollock D, Schiffrin EL, Webb D. The Role of Endothelin-1 in Clinical Hypertension: 20 years on. Hypertension. 2008;52:452-459.
115. Schiffrin EL, Paradis P. Editorial: Suppression of PPAR- activity by angiotensin II in vascular smooth muscle involves Bcr kinase: The fire that drowns the water. Circ Res. 2009; 104:4-6.
116. Padwal RS, Hemmelgarn BR, Khan NA, Grover S, McAlister FA, McKay DW, Wilson T, B Penner MD, Burgess E, Bolli P, Hill M, Mahon J, Myers MG, Abbott C, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Cloutier L, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Bell C, Lebel M, Tobe SW, for the Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol 2009;25:279-286.
117. Khan NA, Hemmelgarn BR, Herman RJ, Leiter LA, Mahon JL, Bell CM, Rabkin SW, Hill MD, Touyz RM, Padwal RS, Larochelle P, Feldman RD, Schiffrin EL, Campbell NRC, Arnold MO, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P MD, Fodor G, Carruthers G, Burns KD, Prasad R, Ruzicka M, deChamplain J, Pylypchuk G, Petrella R, Boulanger J-M, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Katzmarzyk P, Lewanczuk RZ, Tobe S for the Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 2- Therapy. Can J Cardiol 2009;25:287-298.
118. Javeshghani D, Schiffrin EL, Sairam MR, Touyz RM. Potentiation of Vascular Oxidative Stress and nitric oxide-mediated Endothelial Dysfunction by High Fat Diet in a Mouse Model of Estrogen Deficiency and Hyperandrogenemia. J Amer Soc Hypert. 2009;3:295-305.
119. Schiffrin EL. In Memoriam: Jacques de Champlain, M.D., Ph.D. Hypertension. 2009;54:689.
120. Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens. 2009;27:2192-2200.
121. Lemarié CA, Simeone SMC, Nikonova A, Ebrahimian T, Deschênes M-E, Coffman TM, Paradis P, Schiffrin EL. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res. 2009;105;852-859.
122. Marchesi C, Ebrahimian T, Angulo O, Paradis P, Schiffrin EL. Endothelial NO synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension. 2009;54:1384-1392.
123. Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg M J. Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review of Randomized Controlled Trials. Amer J Med. 2009;122:e1-e8.
124. Grassi G, Seravalle G, Brambilla G, Dell’Oro R, Fattori L, Quarti-Trevano F, Bolla GB, Mozzi E, Schiffrin EL, Mancia G. Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. Obesity. 2010;18:92–98.
125. Savoia C, Ebrahimian T, Lemarié CA, Iglarz M, Amiri F, Javeshghani D, Schiffrin EL. Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: Role of oxidative stress and PRMT-1. Clin Sci. 2010;118:583-592.
126. Schiffrin EL. T lymphocytes: A role in hypertension? Invited review. Current Opinion in Nephrol Hypertension. 2010, 19:181–186.
127. Bouchentouf M, Paradis P, Zheng J, Forner K, Boivin MN, Cuerquis J, Boulassel MR, Schiffrin EL, Routy JP, Galipeau J. Monocyte derivatives promote angiogenesis and myocyte survival in a mouse model of myocardial infarction. Cell Transplantation. 2010;19:369-386.
128. Lemarié CA, Schiffrin EL. Angiotensin II type 2 receptor in cardiovascular disease. J Renin Ang Aldo System. 2010;11:19-31.
129. Viel EC, Lemarié CA, Benkirane K, Paradis P, Schiffrin EL. Immune regulation and vascular inflammation in genetic hypertension. Amer J Physiol Heart Circ Physiol. 2010;298:H938-H944.
130. Fagard RH, Grassi G, Hall J, Harrap S, Lindholm LH, Schiffrin EL, Heagerty AM. International Society of Hypertension Low and Middle Income Countries Committee: Review of the Goals of the Committee and of 5 years of ISH activities in Low and Middle Income Countries. J Hypertens. 2010;28:635–636.
131. Briet M and Schiffrin EL. Aldosterone effects on the kidney and cardiovascular system, and clinical value of aldosterone antagonism. Nature Reviews Nephrology. 2010;6:261–273.
132. Amiri F, Ko EA, Javeshghani D, Reudelhuber TL, Schiffrin EL. Deleterious combined effects of aging, salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function. J Hypertens 2010;28:1243-1251.
133. Schiffrin EL. How are stressed prehypertensive rats pressured? Endothelin pleads guilty. Editorial Commentary. Hypertension. 2010;56:191-192.
134. Rehman A, Schiffrin EL. Vascular Effects of Antihypertensive Drug Therapy. Curr Hypertens Rep. 2010;12:226-232.
135. Grassi G, Schiffrin EL. Media-to-lumen ratio as predictor of renal abnormalities in hypertension: new findings, new questions. Editorial Commentary. J Hypertens. 2010;28:1811-1813.
136. Leenen FH, Schiffrin EL. Control rates of Hypertension in North America. Editorial. Hypertension. 2010;56:571-572.
137. Schiffrin EL. Circulatory Therapeutics : Use of antihypertensive agents and their effects on the vasculature. J Cell Mol Med. 2010;14:1018–1029.
138. Motillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg M J. The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis. J Amer Coll Cardiol. 2010;56:1113-1132.
139. Ducharme A, Schiffrin EL. Reviewing the future of RAS blockade: The role of ACE inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation. Can J Cardiol. 2010;26(Suppl E):21E-23E.
140. Schiffrin EL. Antioxidants in hypertension and cardiovascular disease. Mol Interventions. 2010;10(6):354-62.
141. Bouchentouf M, Forner KA, Cuerquis J, Michaud V, Zheng J, Paradis P, Schiffrin EL, Galipeau J. Induction of cardiac angiogenesis requires killer cell lectin-like receptor 1 and α4β7 integrin expression by NK cells. J Immunol. 2010;185:7014-7025.
142. Simeone SMC, Li MW, Paradis P, Schiffrin EL. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol Genomics. 2011;43:148-160.
143. Ebrahimian T, Lemarié CA, Simeone S, Pagano PJ, Gaestel M, Paradis P, Wassmann S, Schiffrin EL. MAP Kinase-activated protein kinase 2 in angiotensin II-induced inflammation: Regulation of p47phox and antioxidants. Hypertension. 2011;57:245-54.
144. Barhoumi T, Kasal DAB, Li MW, Shbat L, Laurant P, Fritsch Neves M, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011; 57: 469-476.
145. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypert Reports. 2011;13:163-172.
146. Lemarié CA, Shbat L, Marchesi C, Angulo OJ, Deschênes M-E, Blostein MD, Paradis P, Schiffrin EL. Mthfr deficiency induces endothelial progenitor cell senescence via uncoupling of eNOS and downregulation of SIRT1. Amer J Physiol Heart Circ Physiol. 2011;300:H745-53.
147. Quinn RR, Padwal RS, Hemmelgarn BR, Myers MG, Cloutier L, Bolli P, McKay DW, Hill M, Mahon J, Grover S, Wilson T, Penner B, Burgess E, McAlister FA, Lamarre-Cliche M, Mclean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, KD Burns, Ruzicka M, Campbell NRC, Vallée M, Prasad R, Lebel M, Tobe SW, for the Canadian Hypertension Education Program. The 2010 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol. 2011;26:241-248.
148. Hackam D, Nadia A. Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NRC, Padwal R, Campbell TS, Lindsay MP, Hill M, Quinn RR, Mahon J, Herman RJ, Schiffrin EL, Ruzicka M, Larochelle P, Feldman RD, Lebel M, Poirier L, Arnold JMO, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Boulanger J-M, Sharma M, Hamet P, Fodor G, Carruthers SG, Pylypchuk G, Burgess ED, Burns KD, Vallée M, Prasad R, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Tobe SW, for the Canadian Hypertension Education Program. The 2010 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Part 2 – Therapy. Can J Cardiol. 2011;26:249-258.
149. Sierra C, Coca A, Schiffrin EL. Vascular mechanisms in the pathogenesis of stroke. Curr Hypert Rep. 2011;13:200-207.
150. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids. 2011;76:834–839.
151. Liu X, Liu M, Tsilimingras D, Schiffrin EL. Racial disparities in cardiovascular risk factors among diagnosed hypertensive subjects. J Amer Soc Hypert. 2011;5:239-248.
152. Thorogood A, Mottillo S, Shimony A, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Schiffrin EL, Eisenberg MJ. Aerobic Exercise and Weight Loss: Meta-Analysis of Randomized Controlled Trials. Amer J Med. 2011;124: 747-755.
153. Lemaire M, Lemarié CA, Flores Molina M, Schiffrin EL, Lehoux S, Mann KK. Exposure to Environmentally-Relevant Arsenic Concentrations Increases Atherosclerosis in ApoE-/- Mouse Model. Toxicological Sci. 2011;122:211-221.
154. Callera GE, Yogi A, Briones AM, Montezano ACI, He Y, Tostes RCA, Schiffrin EL, Touyz RM. Vascular inflammation by aldosterone is mediated via c-src trafficking through cholesterol-rich microdomains. Cardiovasc Res. 2011;91:720-731.
155. Marchesi C, Essalmani R, Lemarié C, Leibovitz E, Ebrahimian T, Paradis P, Seidah NG, Schiffrin EL, Prat A. Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: Role of fibroblast autophagy. J Mol Med. 2011;89:1103-1111.
156. Bouchentouf M, Forner K, Cuerquis J, Boulassel MR, Routy JP, Waller EK, Quyyumi AA, Paradis P, Schiffrin EL, Galipeau J. Novel and simplified method of culture of human blood derived early endothelial progenitor cells for the treatment of ischemic vascular disease. Cell Transplantion. 2011;20:1431-1443.
157. Leibowitz A, Schiffrin EL. Immune Mechanisms in Hypertension. Current Hypert Reports. 2011;13:465–472.
158. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, Cloutier L, Bolli P, Hill MD, Wilson T, Penner B, Burgess E, Lamarre-Cliché M, McLean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Burns KD, Ruzicka M, Campbell NR, Vallée M, Prasad GV, Lebel M, Campbell TS, Lindsay MP, Herman RJ, Larochelle P, Feldman RD, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Lewanczuk R, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Poirier L, Tobe SW; Canadian Hypertension Education Program. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2011;27:415-433.e2.
159. Bouchentouf M, Williams P, Forner K-A, Cuerquis J, Michaud V, Paradis P, Schiffrin EL, Galipeau J. Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction. Cytokine. 2011;56:732-738.
160. Marchesi C, Dentali F, Nicolini F, Maresca AM, Tayebjee MH, Franz M, Guasti L, Venco A, Schiffrin EL, Lip GYH, Grandi AM. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: A systematic review and meta-analysis. J Hypertens. 2012; 30:3-16.
161. Schiffrin EL. Immune modulation of resistance artery remodeling. Basic Clin Pharmacol Toxicol 2012;110:70-72.
162. Schiffrin EL. Effect of treatment on cardiac small resistance arteries in hypertension and diabetes. J Hypertens. 2012;30:271-272.
163. Rautureau Y, Schiffrin EL. Endothelin in hypertension: An update. Curr Opinion Nephrol Hypert. 2012, 21:128–136.
164. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2012;59:291-299.
165. Kasal DAB, Barhoumi T, Li MW, Fritsch Neves M, Laurant P, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012;59:324-330.
166. Schiffrin EL. 2011 Excellence Award in Hypertension Research Lecture. Vascular remodeling in hypertension: Mechanisms and treatment. Hypertension. 2012; 59:367-374.
167. Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, Rabkin SW, Rabi DM, Gilbert RE,Padwal RS, Dawes M, Touyz RM, Campbell TS, Cloutier L, Grover S, Honos G, Herman RJ, Schiffrin EL, Bolli P, Wilson T, Feldman RD, Lindsay MP, Hemmelgarn BR, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad RVR, Lebel M, McLean D, Arnold JMO, Moe GW, Howlett JG, Boulanger J-M, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V Kaczorowski J, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Lamarre-Cliché M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk G, Burgess E, Lewanczuk R, Dresser GK, Penner B, Hegele RA, McFarlane PA, Sharma M, Campbell NRC, Reid D, Poirier L, and Tobe SW, for the Canadian Hypertension Education Program. The 2012 Canadian Hypertension Education Program (CHEP) Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk and Therapy. Can J Cardiol 2012;28:270-287.
168. Kasal DAB, Schiffrin EL. Angiotensin II, aldosterone and anti-inflammatory lymphocytes: interplay and therapeutic opportunities. Int J Hypertens. 2012: Article ID 829786, 5 pages, DOI: 10.1155/2012/829786.
169. Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F Ruether D, Myers M, Bjarnason G. Hypertension Management in Renal Cell Cancer Patients Treated with Anti-Angiogenic Agents. Curr Oncol 2012;19: 202-208.
170. Sedeek M, Montezano AC, Hebert RL, Gray SP, Di Marco E, Jha JC, Cooper ME, Jandeleit-Dahm K, Schiffrin EL, Wilkinson-Berka JL, Touyz RM. Oxidative stress, Nox isoforms and complications of diabetes – Potential targets for novel therapies. J Cardiovasc Trans Res. 2012;5:509-518.
171. Schiffrin EL. Hypertension: treatments, diabetes, and developing regions. The Lancet. 2012;380(9841): 539-541.
172. Cloutier L, Schiffrin EL. Hypertension prevalence and control: Impact of method of blood pressure measurement. Current Cardiovasc Risk Rep. 2012;6(4):267-273; DOI: 10.1007/s12170-012-0247-z.
173. Lipman M, Schiffrin EL. What is the ideal blood pressure goal for patients with diabetes mellitus and nephropathy? Curr Opin Cardiol. 2012;14:651–659.
174. Schiffrin EL. The immune system: role in hypertension. Can J Cardiol. 2013;29(5):543-548. doi.org/10.1016/j.cjca.2012.06.009. PMID: 22902155.
175. Briet M, Schiffrin EL. Treatment of arterial remodeling in essential hypertension. Curr Hypert Rep. 2013;15(1):3-9. doi: 10.1007/s11906-012-0325-0.
176. Briet M, Schiffrin EL. Vascular actions of aldosterone. Invited review. J Vasc Res. 2013;50:89-99. DOI: 10.1159/000345243.
177. Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S. The use of angiotensin receptor blockers and the risk of cancer: a nested case-control study. PLoS One. 2012;7(12):e50893. doi: 10.1371/journal.pone.0050893. PMID: 23251399.
178. Schiffrin EL. Vascular mineralocorticoid receptors regulate blood pressure: Effects on myogenic tone and role in aging. Invited commentary on “Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors” by McCurley et al. (Nature Medicine 2012;18:1429-1433.). Circ Res. 2013;112:415-417. PMID: 23371898.
179. Marchesi C, Rehman A, Rautureau Y, Kasal DAB, Briet M, Leibowitz A, Simeone SMC, Neves MF, Offermanns S, Gonzalez FJ, Paradis P, Schiffrin EL. Protective Role of Vascular Smooth Muscle Cell PPAR in Angiotensin II-induced Vascular Disease. Cardiovasc Res. 2013; 97: 562-570.
180. Sheppard R, Schiffrin EL. Inhibition of the renin-angiotensin system for lowering coronary artery disease risk. Curr Opin Pharmacol. 2013;13:274–279. doi.org/10.1016/j.coph.2013.03.00. PMID: 23523606.
181. Briet M, Barhoumi T, Rehman MMO, Sierra C Boutouyrie P, Nessim SJ, Frisch G, Paradis P, Lipman ML, Schiffrin EL. Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease: Role of oxidative stress and endothelin-1. J Amer Heart Assoc. 2013;2:e000128. doi: 10.1161/JAHA. PMID: 23584809.
182. Leibowitz A, Rehman A, Paradis P, Schiffrin EL. Role of T regulatory lymphocytes in the pathogenesis of high-fructose diet-induced metabolic syndrome. Hypertension. 2013;61:1316-1321. Doi: 10.1161/HYPERTENSIONAHA.111.203521. Epub 2013 Mar 25. PMID: 23529169
183. Javeshghani D, Barhoumi T, Idris-Khodja N, Paradis P, Schiffrin EL. Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury. Hypertension. 2013;62:112-117. DOI: 10.1161/HYPERTENSIONAHA.113.01298. PMID: 23670300.
184. Davis MI, Filion KB, Zhang D, Eisenberg MJ, Afilalo J, Schiffrin EL, Joyal D. Effectiveness of Renal Denervation Therapy for Resistant Hypertension: A Systematic Review and Meta-Analysis. J Amer Coll Cardiol 2013;62:231-241. DOI: 10.1016/j.jacc.2013.04.010. PMID: 23644092.
185. Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, Khan NA, Herman RJ, Bacon SL, Cloutier L, Dawes M, Rabkin SW, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Feldman RD, Lindsay P, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Sharma M, Reid DJ, Tobe SW, Poirier L, Padwal RS; Canadian Hypertension Education Program. The 2013 Canadian Hypertension Education Program (CHEP) Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2013;29:528-542. doi:10.1016/j.cjca.2013.01.005. PMID: 23541660.
186. Schiffrin EL. Immune mechanisms in hypertension: How do T regulatory lymphocytes fit in? Editorial commentary. J Hypertens 2013;31:1944-1945. PMID: 24107725.
187. Li MW, Mian MOR, Barhoumi T, Rehman A, Mann, K, Paradis P, Schiffrin EL. Endothelin-1 overexpression exacerbates atherosclerosis and induces abdominal aortic aneurysms in apolipoprotein E knockout mice. Atheroscl Thromb Vasc Biol. 2013;33:2306-2315. doi: 10.1161/ATVBAHA.113.302028. Epub 2013 Jul 25. PMID: 23887640.
188. Mian MOR, Idris-Khodja N, Li MW, Leibowitz A, Paradis P, Rautureau Y, Schiffrin EL. Preservation of endothelium-dependent relaxation in atherosclerotic mice with endothelium-restricted endothelin-1 overexpression. J Pharmacol Exptl Ther 2013; 347:30-37. doi:10.1124/jpet.113.206532. PMID: 23902937.
189. Davis MI, Filion KB, Eisenberg MJ, Afilalo J, Schiffrin EL, Joyal D. Reply to Letter to the Editor: No Support for Renal Denervation in a Meta-Analysis. J Am Coll Cardiol. 2013. doi: 10.1016/j.jacc.2013.09.009. PMID: 24055847.
190. Schiffrin EL. Immune mechanisms in hypertension and vascular injury. Clin Sci. 2013; 126:267-274. PMID: 24144355.
191. Bertagnolli M, Huyard F, Cloutier A, Anstey Z, Huot-Marchand J-E, Fallaha C, Paradis P, Schiffrin EL, deBlois D, Nuyt AM. Transient neonatal high oxygen exposure leads to early adult cardiac dysfunction, remodeling and activation of the renin-angiotensin system. Hypertension 2014;63:143-150. PMID: 24166752
192. Mian MOR, Paradis P, Schiffrin EL. Innate Immunity in Hypertension. Curr Hypert Rep. 2014; 16:413-422. DOI: 10.1007/s11906-013-0413-9. PMID: 24407446.
193. Weber MA, Schiffrin EL, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram VS, Cohen DL, Cader J-C, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramírez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB, White WB. Clinical Practice Guidelines for the Management of Hypertension in the Community: A Statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3-15. doi: 10.1097/HJH.0000000000000065. PMID: 24270181.
194. Campbell NRC, Lackland D, Chockalingam A and Lisheng L), and the Executive Committee of the International Society of Hypertension (Harrap S, Touyz RM, Burrell L, Ramírez A, Schmieder R, Schutte A, Prabhakaran D, Schiffrin EL. The International Society of Hypertension and World Hypertension League call on governments, non governmental organizations and the food industry to work to reduce dietary sodium. J Hypertens. 2014;32:446–447. doi: 10.1097/HJH.0000000000000079. PMID: 24430121.
195. Schiffrin EL. Inflammation, immunity and development of essential hypertension. Editorial Comment. J Hypertens. 2014;32:228-229. doi: 10.1097/HJH.0000000000000042. PMID: 24430118.
196. Barhoumi T, Briet M, Kasal DA, Laurant P, Paradis P, Schiffrin EL. Erythropoietin induced hypertension and vascular injury in mice overexpressing human endothelin-1: exercise attenuated hypertension, oxidative stress, inflammation and immune response. J Hypertens 2014;32(4):784-794. PMID: 24463938.
197. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, Rabkin SW, Trudeau L, Feldman RD, Cloutier L, Prebtani A, Herman RJ, Bacon SL, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Lindsay P, Hill MD, Coutts SB, Gubitz G, Gelfer D, Vallée M, Prasad GVR, Lebel M, McLean D, Arnold JMO, Moe GW, Howlett JG, Boulanger J-M, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Burns KD, Petrella RJ, Hiremath S, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Khara M, Pipe A, Oh P, Selby P, Sharma M, Reid D, Tobe SW, Padwal RS, Poirier L, for the Canadian Hypertension Education Program. The 2014 Canadian Hypertension Education Program (CHEP). Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention and Treatment of Hypertension. Can J Cardiol. 2014;30:485-501. doi: 10.1016/j.cjca.2014.02.002.. PMID: 24786438.
198. Schiffrin EL. SPS3: Blood pressure targets after lacunar stroke supported by statistically not significant results: Should these be the basis for recommendations or caution? In Controversies in hypertension: Optimum blood pressure targets after lacunar stroke, Con position. Hypertension. 2014;63:923-924. doi:10.1161/HYPERTENSIONAHA.113.02529. PMID: 24591334.
199. Idris-Khodja N, Mian MOR, Paradis P, Schiffrin EL. Dual Roles of Adaptive Immunity in Hypertension. Eur Heart J. 2014;35(19):1238-1244. doi: 10.1093/eurheartj/ehu119. PMID: 24685711.
200. Freel EM, Perry CG, O’Dwyer P, Staessen JA, Jennings GL, Granger JP, De Buyzere M, Schiffrin EL. Clinico-Pathological Conference: An unusual cause of mineralocorticoid hypertension. Hypertension 2014;64:689-692. PMID: 25156173.
201. Mark PB, Schiffrin EL, Jennings GL, Dominiczak AF, Wang J-G, De Buyzere M, Staessen JA. Clinico-Pathological Conference: Renovascular hypertension- to stent or not to stent? Hypertension 2014;64:1165-1168. PMID: 25245390
202. Campbell NR1, Lackland DT, Niebylski ML; World Hypertension League and International Society of Hypertension Executive Committees (Schiffrin EL). High blood pressure: why prevention and control are urgent and important-a 2014 fact sheet from the World Hypertension League and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(8):551-553. doi: 10.1111/jch.12372. PMID: 25040331.
203. Atallah R, Filion KB, Wakil SM, Genest J, Joseph L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The Long-Term Effects of Four Popular Diets on Weight Loss and Cardiovascular Risk Factors: A Systematic Review of Randomized Controlled Trials. Circulation Cardiovasc Quality Outcomes 2014;7(6):815-27. doi: 10.1161/CIRCOUTCOMES.113.000723. PMID: 25387778
204. Davis M, Schiffrin EL, Joyal D. Renal denervation therapy for resistant hypertension. Curr Treat Options Cardiovasc Med. 2014;16:350. doi: 10.1007/s11936-014-0350-1. PMID: 25300359.
205. Barton M, Schiffrin EL. In Memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research. Life Sci. 2014. 118(2):91-96. doi:10.1016/j.lfs.2014.08.011. PMID 25152472.
206. Perry CG, Freel EM, O’Dwyer P, Schiffrin EL, Jennings GL, Dominiczak AF, De Buyzere M. Clinico-Pathological Conference: A rare cause of severe hypertension in a young woman. Hypertension 2015:65:21-24. doi:10.1161/HYPERTENSIONAHA.114.04619. PMID: 25385763
207. Ferrario CM, Schiffrin EL. Translational Success Stories: Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease. Circ Res. 2015; 116: 206-213. doi: 10.1161/CIRCRESAHA.116.302706. PMID: 25552697.
208. Blom K, Farina S, Gomez Y-H, Campbell NRC, Hemmelgarn B, Cloutier L, Mackay DW, Dawes M, Tobe SW, Bolli P, Gelfer M, Mclean D, Bartlett G, Joseph L, Featherstone R, Schiffrin EL, Daskalopoulou SS. MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): a Study Protocol. Curr Hypertens Rep (2015) 17: 22. https://doi.org/10.1007/s11906-015-0533-5. PMID: 25790798.
209. Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, McKay DW, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Ramesh Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Brian Penner S, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Stone JA, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Fournier A, Lewanczuk R, Dresser GK, Sharma M, Reid D, Benoit G, Feber J, Harris KC, Poirier L, Padwal RS. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2015 May;31(5):549-68. doi: 10.1016/j.cjca.2015.02.016. PMID: 25936483.
210. Rautureau Y, Coelho SC, Fraulob-Aquino JC, Huo K-G, Rehman A, Offermanns S, Paradis P, Schiffrin EL. Inducible human endothelin-1 overexpression in endothelium raises blood pressure via endothelin type A receptors. Hypertension. 2015; 66:347-355. DOI: 10.1161/HYPERTENSIONAHA.115.05168. PMID: 2610134.
211. Townsend R, Wilkinson I, Schiffrin EL, Avolio A, Bradley TJ, Chirinos JA, Cockcroft J, Ellison D, Heffernan K, Lakatta EG, McEniery C, Mitchell GF, Najjar S, Nichols W, Urbina E, Weber T; on behalf of the American Heart Association Council on Hypertension. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. A Scientific Statement of the American Heart Association. Hypertension. 2015;66:698-722. DOI: 10.1161/HYP.0000000000000033. PMID: 26160955.
212. Schiffrin EL. Mechanisms of remodelling of small arteries, antihypertensive therapy and the immune system in hypertension. Clin Invest Med. 2015;38:E394-E402. PMID: 26654522.
213. Mian MOR, Barhoumi T, Briet M, Paradis P, Schiffrin EL. Deficiency of T regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J Hypertens 2016, 34:97–108. DOI:10.1097/HJH.0000000000000761. PMID: 2663021.
214. Schiffrin EL, Campbell NRC, Feldman RD, Kaczorowski J, Lewanczuk R, Padwal R, Tobe S. Hypertension in Canada: Past, Present and Future. Ann Global Health. 2016;82:288-299. DOI: 10.1016/j.aogh.2016.02.006. PMID: 27372532.
215. Schiffrin EL, Calhoun D, Flack JM, Ito S, Webb RW. A message from the new editorial team at the American Journal of Hypertension. Amer J Hypert. 2016;29:1. doi:10.1093/ajh/hpv173
216. Schiffrin EL, Calhoun D, Flack JM. SPRINT proves that lower is better for non diabetic high risk patients, but at a price. Amer J Hypert. 2016;29;2-4. doi:10.1093/ajh/hpv190. PMID: 26597221.
217. Bertagnolli M, Dios A, Béland-Bonenfant S, Gascon G, Sutherland M, Lukaszewski M-A, Cloutier A, Paradis P, Schiffrin EL, Nuyt AM. Neonatal activation of the renin-angiotensin system in high oxygen-exposed newborn rats: angiotensin receptor blockade prevents the developmental programming of cardiac dysfunction. Hypertension. 2016;67(4):774-782. doi: 10.1161/HYPERTENSIONAHA.115.06745. PMID: 26857347.
218. Caillon A, Schiffrin EL. Role of Inflammation and Immunity in Hypertension: Recent Epidemiological, Laboratory and Clinical Evidence. Curr Hypert Rep. (2016) 18: 21. https://doi.org/10.1007/s11906-016-0628-7. PMID: 26846785.
219. Campbell NR, Gelfer M, Stergiou GS, Alpert BS, Myers MG, Rakotz MK, Padwal R, Schutte AE, O'Brien E, Lackland DT, Niebylski ML, Nilsson PM, Redburn KA, Zhang XH, Burrell L, Horiuchi M, Poulter NR, Prabhakaran D, Ramirez AJ, Schiffrin EL, Touyz RM, Wang JG, Weber MA. A Call to Regulate Manufacture and Marketing of Blood Pressure Devices and Cuffs: A Position Statement From the World Hypertension League, International Society of Hypertension and Supporting Hypertension Organizations. J Clin Hypertens (Greenwich). 2016;18:378-380. doi: 10.1111/jch.12782. PMID: 26852890.
220. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Harris KC, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; CHEP Guidelines Task Force. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2016;32:569-588. doi: 10.1016/j.cjca.2016.02.066. PMID: 27118291.
221. Briet M, Barhoumi T, Mian MOR, Coffman TM, Paradis P, Schiffrin EL. Aldosterone-induced vascular remodeling and endothelial dysfunction requires functional angiotensin II type 1a receptors. Hypertension. 2016;67: 897–905. DOI: 10.1161/HYPERTENSIONAHA.115.07074. PMID: 27045029.
222. Padwal RS, Rabi DM, Schiffrin EL. Guidelines Debate: Recommendations for Intensive Blood Pressure Lowering in High Risk Patients, the Canadian Viewpoint. Hypertension. 2016;68:3-5. DOI: 10.1161/HYPERTENSIONAHA.116.07573. PMID: 27160203.
223. Weber MA, Poulter NR, Schutte AE, Burrell L, Horiuchi M, Prabhakaran D, Ramirez A, Wang JG, Schiffrin EL, Touyz RM. Is it time to reappraise blood pressure thresholds and targets? Statement from the International Society of Hypertension – a global perspective. Hypertension. 2016;68:266-268. DOI: 10.1161/HYPERTENSIONAHA.116.07818. PMID: 27354426.
224. Schiffrin EL, Calhoun DA, Flack JM. Editorial. Do we need a new definition of hypertension after SPRINT? Amer J Hypert. 2016;29:1127-1129. doi:10.1093/ajh/hpw068. PMID: 27334926.
225. Campbell NR, Khalsa T; World Hypertension League Executive: Lackland DT, Niebylski ML, Nilsson PM, Redburn KA, Orias M, Zhang XH; International Society of Hypertension Executive: Burrell L, Horiuchi M, Poulter NR, Prabhakaran D, Ramirez AJ, Schiffrin EL, Touyz RM, Wang JG, Weber MA; World Stroke Organization; International Diabetes Federation; International Council of Cardiovascular Prevention and Rehabilitation; International Society of Nephrology. High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. J Clin Hypertens (Greenwich). 2016;18:714-717. doi: 10.1111/jch.12840. PMID: 27316336.
226. Idris-Khodja N, Ouerd S, Mian MOR, Gornitsky J, Barhoumi T, Paradis P, Schiffrin EL. Endothelin-1 overexpression exaggerates diabetes-induced endothelial dysfunction by altering oxidative stress. Amer J Hypert. 2016;29:1245-1251. doi: 10.1093/ajh/hpw078. PMID: 27465439.
227. Campbell NRC, Lackland DT, Niebylski M L, Orias M, Redburn KA, Nilsson PM, Zhang X-H, Burrell L, Horiuchi M, Poulter NR, Prabhakaran D, Ramirez AJ, Schiffrin EL, Schutte AE, Touyz RM, Wang J-G, Weber MA, and International Council of Cardiovascular Prevention and Rehabilitation. 2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation. J Clin Hypertens. 2016;(11)18:1082-1085. doi:10.1111/jch.12894. PMID: 27515460.
228. Francesca Bosetti, Zorina S. Galis, Margaret S. Bynoe, Marc Charette, Marilyn J. Cipolla, Gregory J. del Zoppo, Douglas Gould, Thomas S. Hatsukami, Teresa L. Z. Jones, James I. Koenig, Gerard A. Lutty, Christine Maric‐Bilkan, Troy Stevens, H. Eser Tolunay, Walter Koroshetz, the “Small Blood Vessels: Big Health Problems” Workshop Participants, Dritan Agalliu, David A. Antonetti, Manfred Boehm, Claudette E. Brooks, Kathleen M. Caron, William Chilian, Mat J. Daemen, Robert D'Amato, Thomas P. Davis, Adviye Ergul, James E. Faber, Ariel R. Gomez, Peter Grayson, Isabella Grumbach, Jaime Grutzendler, Chenghua Gu, David Gutterman, John Hallenbeck, Ira Herman, Jay Humphrey, Costantino Iadecola, Edward W. Inscho, David Kleinfeld, Eng H. Lo, Jose A. Lopez, Stephen Macknik, Asrar Malik, Tanya N. Mayadas, Dorian McGavern, Gerald A. Meininger, Virginia M. Miller, Maiken Nedergaard, Mark T. Nelson, Shayn Peirce‐Cottler, Ipolia Ramadan, Gary A. Rosenberg, Ernesto L. Schiffrin, Peter Searson, Nina Stachenfeld, Radu V. Stan, Yajaira Suarez, Eroboghene E. Ubogu, Zinaida S. Vexler, Cornelia M. Weyand and Berislav V. Zlokovic. Scientific Recommendations of the National Institutes of Health Workshop: Small Blood Vessels, Big Health Problems? Journal of the American Heart Association. 2016;5:e004389. doi.org/10.1161/JAHA.116.004389. PMID: 27815267.
229. Schiffrin EL, Calhoun DA, Flack JM, Ito S, Webb RC. Update from the Editors to our readers. Amer J Hypert. 2017;30(1):1-2. doi: 10.1093/ajh/hpw141. PMID: 27940428.
230. Schiffrin EL. A SPRINT to lower blood pressure targets? In “First-line management of hypertension. Medicographia #131. 2017;39(2).
231. Idris-Khodja N, Ouerd S, Trindade M, Gornitsky J, Rehman A, Barhoumi T, Offermanns S, Gonzalez FJ, Neves MF, Paradis P, Schiffrin EL. Vascular smooth muscle cell peroxisome proliferator-activated receptor γ protects against endothelin-1-induced oxidative stress and inflammation. J Hypertens. 2017;35(7):1390–1401. doi: 10.1097/HJH.0000000000001324. PMID: 28234672.
232. Caillon A, Mian MOR, Fraulob-Aquino JC, Huo K-G, Barhoumi T, Ouerd S, Sinnaeve PR, Paradis P, Schiffrin EL. Gamma Delta T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury. Circulation. 2017; 135:2155–2162. doi.org/10.1161/CIRCULATIONAHA.116.027058. PMID: 28330983.
233. Caillon A, Huo KG, Paradis P, Schiffrin EL. Response by Caillon et al to Letter Regarding Article, "γδ T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury". Circulation. 2017 Nov 28;136(22):2200-2201. doi: 10.1161/CIRCULATIONAHA.117.030517. PMID: 29180499.
234. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Valclée M, Prasad GV, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Klein G, Leiter LA, Jones C, Côté AM, Woo V, Kaczorowski J, Trudeau L, Tsuyuki R T, Hiremath S, Drouin D, Lavoie KL, Hamet P, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM for Hypertension Canada. Hypertension Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can J Cardiol. 2017;33:557-576. DOI: http://dx.doi.org/10.1016/j.cjca.2017.03.005. PMID: 28449828.
235. Kline GA, Prebtani APH, Leung AA, Schiffrin EL. Primary Aldosteronism: A Common Cause of Resistant Hypertension. Can Med Assoc J. 2017;89:E773-E778. doi: 10.1503/cmaj.161486. PMID: 28584041.
236. Kline GA, Prebtani A, Leung AA, Schiffrin EL. The potential role of primary care in case detection/screening of primary aldosteronism. Am J Hypertens 2017;30; 1147–1150. First published June 19, 2017. doi: 10.1093/ajh/hpx064. PMID: 28992276.
237. Messerli FH, Hofstetter L, Agabiti Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams B. Expertise - no longer a sine qua non for Guideline. Simultaneous publication in Hypertension. Hypertension. 2017;70:235-237. DOI: 10.1161/HYPERTENSIONAHA.117.09470; PMID: 28652465; and J. of Hypertens. 2017;35(8):1564–1566. doi: 10.1097/HJH.0000000000001435; PMID: 2865797.
238. Barhoumi T, Mian MOR, Fraulob-Aquino JC, Idris-Khodja N, Huo KG, Rehman A, Ebrahimian T, Lehoux S, Paradis P, Schiffrin EL. Matrix metalloproteinase-2 knockout prevents angiotensin II-induced endothelial dysfunction and vascular remodeling, oxidative stress and inflammation. Cardiovasc Res. 2017; 113:1752-1762. DOI: 10.1093/cvr/cvx115. PMID: 29016715.
Accompanying Editorial: de Jager SCA, Hoefer IE. Beyond the matrix: MMP2 as critical regulator of inflammation-mediated vascular dysfunction. Cardiovasc Res. 2017; 113: 1705-1707. DOI: doi:10.1093/cvr/cvx202.
239. Schiffrin EL. New ACC/AHA Guildline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. International Society of Hypertension HYPERTENSION NEWS. 2017;51:12-15. ISSN: 2520-2782.
240. Schiffrin EL. Debate sobre objetivos de descenso de la presión arterial luego de SPRINT. Rev Argent Cardiol 2017;85:XXX-XXX. http://dx.doi.org/10.7775/rac.es.v85.i4.11763.
241. Coelho SC, Berillo O, Ouerd S, Fraulob-Aquino JC, Caillon A, Barhoumi T, Offermanns S, Paradis P, Schiffrin EL. Three-month endothelial human endothelin-1 overexpression causes blood pressure elevation and vascular and kidney injury. Hypertension. 2018;71:208-216. DOI: 10.1161/ HYPERTENSIONAHA.117.09925.PMID: 29133362.
242. Schiffrin EL. Year in Clinical Hypertension from other pages. Amer J Hypertens. 2018;31:136–138. doi.org/10.1093/ajh/hpx206. PMID: 29186309.
243. Schiffrin EL. Hypertension in 2017: Novel mechanisms of hypertension and vascular dysfunction. Nature Rev Nephrol. 2018;14:73-74. doi: 10.1038/nrneph.2017.178. PMID: 29292372.
244. Flack JM, Calhoun DA, Schiffrin EL. The New ACC/AHA Hypertension Guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults (Editorial). Amer J Hypertens. 2018; 31:133-135. doi.org/10.1093/ajh/hpx207. PMID: 29228096.
245. Schiffrin EL. Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From Canada. Circulation. 2018;137:883-885. doi: 10.1161/CIRCULATIONAHA.117.032849. PMID: 29483168
246. Schiffrin EL. Second Opinion: Does endothelin-1 raise or lower blood pressure in humans? Nephron. 2018;139:47-50. DOI: 10.1159/000487346. PMID: 29448245.
247. Schiffrin EL. In Memoriam Jacques Genest Sr., C.C., MD, MACP, FRCPC. Amer J Hypertens. 2018; 31:385-386. DOI:10.1093/ajh/hpy012.
248. Schiffrin EL. In memoriam: Jacques Genest Sr. Hypertension. 2018;71:548-549. DOI: 10.1161/HYPERTENSIONAHA.118.10875.
249. Paradis P, Schiffrin EL. Editorial: CXCL1-CXCR2 lead monocytes to the heart of the matter. Eur Heart J. 2018; 39:1832-1834. doi:10.1093/eurheartj/ehy114. PMID: 29528395.
250. Cerrato R, Crabtree M, Antoniades C, Kublickiene K, Schiffrin EL, Channon KM, Böhm F. Effects of Endothelin-1 on intracellular tetrahydrobiopterin levels in vascular tissue. Scandinavian Cardiovasc J. 2018;52:163-169. DOI: 10.1080/14017431.2018.1453942. PMID: 29566572.
251. Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, Leiter LA, Jones C, Woo V, Hegele RA, Selby P, Pipe A, McFarlane PA, Oh P, Gupta M, Bacon SL, Kaczorowski J, Trudeau L, Campbell NR, Hiremath S, Roerecke M, Arcand J, Ruzicka M, Prasad GVR, Vallée M, Edwards C, Sivapalan P, Penner SB, Fournier A, Benoit G, Feber J, Dionne J, Magee LA, Logan AG, Côté A-M, Rey E, Firoz T, Kuyper LM, Gabor JY, Townsend RR, for Hypertension Canada. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology. 2018; 34(5):506-525. doi: 10.1016/ j.cjca.2018.02.022. PMID: 29731013.
252. Daskalopoulou SS, Rabi DM, Schiffrin EL, Feldman RD, Padwal RS, Tremblay G, Khan NA. Hypertension Guidelines in the United States and Canada. Are We Getting Closer? Hypertension. 2018 Jun;71(6):976-978. doi: 10.1161/HYPERTENSIONAHA.117.10772. PMID: 29686013.
253. Schiffrin EL. PROCEEDINGS of the 11th International Workshop on Structure and Function of the Vascular System, 8–10 February 2018 in Paris, France. Amer J Hypertens. 2018;31:933. doi: 10.1093/ajh/hpy070.
254. Caillon A, Paradis P, Schiffrin EL. Role of immune cells in hypertension. Brit J Pharmacol. 2019;176(12):1818-1828. doi: 10.1111/bph.14427. PMID: 29952002.
255. Iulita MF, Duchemin S, Vallerand D, Barhoumi T, Alvarez F., Istomine R, Laurent C, Youwakim J, Paradis P, Arbour N, Piccirillo CA, Schiffrin EL, Girouard H. CD4+ Regulatory T lymphocytes prevent impaired cerebral blood flow in angiotensin II-induced hypertension. J Am Heart Assoc. 2019;8:e009372. DOI: 10.1161/ JAHA.118.009372. PMID: 30572753.
256. Higaki A, Caillon A, Paradis P, Schiffrin EL. Innate and Innate-like Immune System in Hypertension and Vascular Injury. Current Hypert Rep. 2019;21:4. DOI: 10.1007/s11906-019-0907-1. PMID: 30659373.
257. Calhoun DA, Schiffrin EL, Flack JM. Resistant Hypertension: An Update. Editorial. Amer J Hypert., 2019;31:1-3. doi:10.1093/ajh/hpy156. PMID: 30407514.
258. Schiffrin EL. New blood pressure cut-offs, prevalence of hypertension and control, and mood disorders: Are patients benefiting from lower cut-offs for defining hypertension? Editorial. Eur Heart J. 2019;40:739–742. https://doi.org/10.1093/eurheartj/ehy891. PMID: 30624628.
259. Huo K-G, Richer C, Berillo O, Mahjoub N, Fraulob-Aquino JC, Barhoumi T, Ouerd S, Coelho SC, Sinnett D, Paradis P, Schiffrin EL. miR-431-5p knockdown protects against angiotensin II-induced hypertension and vascular injury. Hypertension. 2019;73:1007–1017. DOI: 10.1161/HYPERTENSIONAHA.119.12619. PMID: 30929512.
260. Zack R, Okunade O, Olson E, Salt M, Amodeo C, Anchala R, Berwanger O, Campbell N, Chia Y-C, Damasceno A, Do TNP, Tamdja Dzudie A, Fiuza M, Mirza F, Nitsch D, Ogedegbe G, Podpalov V, Schiffrin EL, Carneiro AV, Lamptey P. Improving Hypertension Outcome Measurement in Low- And Middle-Income Countries. Hypertension. 2019; 73:990–997. Doi: 10.1161/HYPERTENSIONAHA.118.11916. PMID: 30929516.
261. Carcel C, Neal B, Rodgers K, Oparil S, NarkiewiczK, Wang J, Schiffrin EL, Azizi MP, Poulter N, Chalmers. Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment resistant hypertension: the SPIRIT study. J Hypertens. 2019;37:2216-2224. doi: 10.1097/HJH.0000000000002184. PMID:31415307
262. Jurrissen TJ, Grunewald ZI, Woodford ML, Winn NC, Ball JR, Smith TN, Wheeler A, Rawlings AL, Staveley-O’Carroll KF, Ji Y, Fay WP, Paradis P, Schiffrin EL, Vieira-Potter VJ, Fadel PJ, Martinez-Lemus LA, Padilla J. Overproduction of endothelin-1 impairs glucose tolerance but does not promote visceral adipose tissue inflammation or limit metabolic adaptations to exercise. Amer J Physiol (Endo Metab). Am J Physiol Endocrinol Metab. 2019;317: E548–E558. doi: 10.1152/ajpendo.00178.2019. PMID: 31310581.
263. Khan N, Bell A, Berg A,Campbell A, Kacorowski J, Rabi D, Schiffrin EL, Tsuyuki RT. A Call to Action to Implement Prescribing Authority to Pharmacists for Hypertension Management. Can Pharm J (Ott). 2019;52(5):285-287. doi: 10.1177/1715163519866144. PMID: 31534583.
264. Schiffrin EL, Engert JC. Periodontitis and hypertension: causally linked by immune mechanisms. Editorial. Eur Heart J. 2019;40:3471-3473. Doi: 10.1093/eurheartj/ehz729. PMID: 31589300.
265. Grunewald ZI, Jurrissen TJ, Woodford ML, Ramirez-Perez FI, Park LK, Pettit-Mee R, Ghiarone T, Brown SM, Morales-Quinones M, Ball JR, Staveley-O’Carroll KF, Aroor AR, Fadel PJ, Paradis P, Schiffrin EL, Bender SB, Martinez-Lemus LA, Padilla J. Chronic elevation of endothelin-1 alone may not be sufficient to impair endothelium-dependent relaxation. Hypertension. 2019; 74:1409-1419. DOI:10.1161/HYPERTENSIONAHA.119.13676. PMID: 31630572.
266. Rabi DM, McBrien K, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski S, Butalia ScS, Leung AA, Harris KC, Cloutier L, Zarnke KB, Ruzicka M, Hiremath S, Feldman RS, Tobe SW, Campbell TS, Bacon SL, Nerenberg KA, Dresser GK, Fournier A, Burgess E, Lindsay PP, Rabkin SW, Prebtani APH, Grover S, Honos G, Bell AD, Daskalopoulou SS, Alfonsi JE, Arcand JA, Audibert F, Benoît G, Bittman J, Bolli P, Côté A-M, Dionne J, Don-Wauchope A, Edwards C, Firoz T, Gabor JY, Gilbert RE, Grégoire JC, Gryn SE, Gupta M, Hannah-Shmouni F, Hegele RA, Herman RJ, Hill MD, Howlett JG, Hundemer GL, Jones J, Kaczorowski J, Khan N, Kuyper LM, Lamarre-Cliche M, Lavoie KL, Leiter LA, Lewanczuk R, Logan AG, Magee LA, Mangat BK, McFarlane PA, McLean D, Michaud A, Milot A, Moe GW, Penner SB, Pipe A, Poppe AY, Rey E, Roerecke M, Schiffrin EL, Selby P, Sharma M, Shoamanesh A, Sivapalan P, Townsend RR, Tran KC, Trudeau L, Tsuyuki RT, Vallée M, Woo V. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2020; 36(5):596-624. doi: 10.1016/j.cjca.2020.02.086.PMID: 32389335.
267. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Editorial. Amer J Hyperten. 2020;33:373-374. doi.org/10.1093/ajh/hpaa057. PMID: 32251498.
268. Touyz RM, Feldman RD, Harrison DG, Schiffrin EL. A new look at the mosaic theory of hypertension. Can J Cardiol. 2020; 36(5):591-592. doi: 10.1016/j.cjca.2020.03.025. PMID: 32389334.
269. Schiffrin EL. How Structure, Mechanics and Function of the Vasculature Contribute to Blood Pressure Elevation in Hypertension. Can J Cardiol. 2020;36(5):648-658. doi: 10.1016/j.cjca.2020.02.003. PMID: 32389338.
270. Berillo O, Huo K-G, Fraulob-Aquino JC, Richer C, Briet, M, Boutouyrie P, Lipman ML, Sinnett D, Paradis P, Schiffrin EL. Circulating let-7g-5p and miR-191-5p are independent predictors of chronic kidney disease in hypertensive patients. Amer J Hypert. 2020;33(6):505–513. Doi: 10.1093/ajh/hpaa031. PMID: 32115655.
271. Zanoli L, Briet M, Empana J, Cunha PG, Mäki-Petäjä KM, Protogerou AD, Tedgui A, Touyz RM, Schiffrin EL, Spronck B, Vlachopoulos C, Boutouyrie P. Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. J Hypertens. 2020;38(9):1682-1698. DOI: 10.1097/HJH.0000000000002508. PMID: 32649623.
272. Shekhar S, Eisenhoffer G, Barrera FJ, Hall JE, Schiffrin EL, Stratakis C, Hannah-Shmouni F. Endocrine Conditions and COVID-19. Horm Metab Res. 2020; 52(07):471-484. DOI:10.1055/a-1172-1352. PMID: 32512611.
273. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Response to Letter to the Editor by Hajra A, Bandyopadhyay D. COVID-19 and ACEI/ARB: not associated? Amer J Hypertens. 2020; 33:789–790. Doi:10.1093/ajh/hpaa077. PMID: 32415836.
274. Schiffrin EL. Compendium on hypertension The Microbiome, Inflammation and Oxidative Stress, the Sympathetic Nervous System and Treatment of Hypertension. Amer J Hypertens. 2020;33:889. DOI: 10.1093/ajh/hpaa159. PMID: 33085955.
275. Barrera FJ, Shekhar S, Wurth R, Moreno-Pena PJ, Ponce OJ, Hajdenberg M, Alvarez-Villalobos NA, Rodíguez-Gutiérrez R, Brito JP, González-González JG, Hall JE, Schiffrin EL, Eisenhoffer G, Porter F, Brito JP, Bornstein SR, Stratakis C, González-González G, Rodíguez-Gutiérrez R, Hannah-Shmouni F. Prevalence of Diabetes and Hypertension and their Associated Risks for Poor Outcomes in COVID-19 Patients: A Systematic Review and Meta-analysis. J Endocr Soc. 2020. bvaa102. doi:10.1210/jendso/bvaa102. PMID: 32885126.
276. Comeau K, Paradis P, Schiffrin EL. Human and Murine Memory  T Cells: Evidence for Acquired Immune Memory in Bacterial and Viral Infections and Autoimmunity. Cellular Immunology. 2020;357:104217. doi: 10.1016/j.cellimm.2020.104217. PMID: 32979762.
277. Berillo O, Ouerd S, Idris-Khodja N, Rehman A, Richer C, Sinnett D, Kwitek AE, Paradis P, Schiffrin EL. Chromosome 2 fragment substitutions in Dahl salt-sensitive rats and RNA sequencing identified Enpep and Hs2st1 as vascular inflammatory modulators. Hypertension. 2021;77:178-189. DOI: 10.1161/HYPERTENSIONAHA.120.15690. PMID: 33161775.
278. Shokoples BG, Paradis P, Schiffrin EL. P2X7: An untapped target for the management of cardiovascular disease. Atheroscl Thromb Vasc Biol. 2021;41: 186-199. doi: 10.1161/ATVBAHA.120.315116. PMID: 32998520.
279. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(1):1-2. DOI: 10.1093/ajh/hpaa214. PMID: 33599749.
280. Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, Inflammation, Immune System and Hypertension. Amer J Hypertens. 2021;34:15–27. DOI: 10.1093/ajh/hpaa137. PMID: 32820797.
281. Schiffrin EL. Estrogen receptors and T cells determine how sex affects aldosterone-induced hypertension. Editorial. Cardiovasc Res. 2021;117(3):655-657. doi:10.1093/cvr/cvaa170. PMID: 32533825.
282. Ouerd S, Idris-Khodja N, Trindade M, Coelho SC, Neves MF, Jandeleit-Dahm KA, Paradis P, Schiffrin EL. Endothelial Cell-Restricted Endothelin-1 Overexpression Worsens Atherosclerosis and Immune Cell Infiltration in Type-1 Diabetes via NOX1. Cardiovasc Res. 2021;117(4):1144–1153. doi:10.1093/cvr/cvaa168. PMID: 32533834.
283. Higaki A, Mahmoud AUM, Paradis P, Schiffrin EL. Role of Interleukin-23/Interleukin-17 Axis in T Cell-Mediated Actions in Hypertension. Cardiovasc Res. 2021;117(5):1274–1283. DOI: 10.1093/cvr/cvaa257. PMID: 32870976.
284. Masi S, Rizzoni D, Taddei S, Widmer RJ, Montezano AC, Lüscher TF, Schiffrin EL, Lanza GA, Touyz RM, Paneni F, Lerman A, Lanza GA, Virdis A. Pathophysiology and assessment of microvascular disease: progress and clinical implications. Expert consensus document on the mechanisms of microvascular dysfunction, its assessment and its clinical impact in humans. Eur Heart J. 2021;42(26):2590–2604. doi: 10.1093/eurheartj/ehaa857. PMID: 33257973.
285. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(2):123–124. doi:10.1093/ajh/hpab030. PMID: 33705538.
286. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(3):229–230. doi:10.1093/ajh/hpab033.
287. Caillon A, Zhao K, Klein KO, Greenwood C, Lu Z, Paradis P, Schiffrin EL. High systolic blood pressure at hospital admission is an important risk factor in models predicting outcome of COVID-19 patients. Amer J Hypertens. 2021;34(3):282-290. doi: 10.1093/ajh/hpaa225. PMID: 33386395.
288. Touyz RM, Schiffrin EL. A Compendium on Hypertension: New Advances and Future Impact. Editorial. Circ Res.2021;128:803–807. DOI: 10.1161/CIRCRESAHA.121.319181.
289. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(4):301–303. doi :10.1093/ajh/hpab044.
290. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. May 2021;34(5):429–431. doi :10.1093/ajh/hpab050.
291. Berillo O, Coelho SC, Mahjoub N, Offermanns S, Paradis P, Schiffrin EL. Aldosterone contributes to the blood pressure elevation, vessel remodeling and norepinephrine sensitivity caused by endothelial human endothelin-1 overexpression in mice. J. Hypertens. 2021;39: 1908-1917. doi: 10.1097/HJH.0000000000002880. PMID: 34039912.
292. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(6):565-566. doi :10.1093/ajh/hpab056.
293. Higaki A, Mahmoud AUM, Paradis P, Schiffrin EL. Automated Detection and Diameter Estimation for Mouse Mesenteric Artery using Semantic Segmentation. J Vasc Res. 2021; 0:1-9. https://doi.org/10.1159/000516842. PMID: 34182554.
294. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(7):667–668. doi :10.1093/ajh/hpab073.
295. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(8):777-778. doi :10.1093/ajh/hpab092.
296. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(9): 891–892. doi :10.1093/ajh/hpab109.
297. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(10): 1011–1013. doi :10.1093/ajh/hpab131.
298. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(11): 1127–1129. doi :10.1093/ajh/hpab144.
299. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2021;34(12):1245–1246. doi :10.1093/ajh/hpab158.
300. Rizzoni D, De Ciuceis C, Paradis P, Szczepaniak P, Schiffrin EL, Guzik TJ. Immune sistem and microvascular remodeling in humans. Invited review. Hypertension. 2022;79: 35(3) 691–705. DOI: 10.1161/HYPERTENSIONAHA.121.17955. PMID: 35098718.
301. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2022;35(1):1-2. doi:10.1093/ajh/hpab174
302. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2022;35(2):113-114. doi:10.1093/ajh/hpab186.
303. Swamy S, Hannah-Shmouni F, Koch CA, Schiffrin EL, Klubo-Gwiezdzinska J, Gubbi S. Hypertension and COVID-19: Updates from the era of vaccines and variants. J Clin & Transl Endocrinology. 27 (2022) 100285. doi: 10.1016/j.jcte.2021.100285. PMID: 34900602.
304. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2022;35(3):209-210. doi:10.1093/ajh/hpab192.
305. Wurth R, Hajdenberg M, Barrera FJ, Shekhar S, Copacino CE, Moreno-Peña PJ, Gharib O, González-González JG, Brito Campana JP, Rodríguez-Gutiérrez R, Porter F, Hiremath S, Hall JE, Schiffrin EL, Stratakis CA, Shmouni FH. Scoping review of COVID-19-related systematic reviews and meta-analyses: can we really have confidence in their results? Postgrad Med J. 2022;98(1159):372-379. doi: 10.1136/postgradmedj-2020-139392. PMID: 33637639.
306. Cheung CY, Biousse V, Keane PA, Schiffrin EL, Wong TY. Hypertensive eye disease. Nature Reviews Disease Primers. 2022. Doi:10.1038/s41572-022-00342-0. PMID: 35273180.
307. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2022;35(4):291–292. doi:10.1093/ajh/hpac016.
308. Berillo O, Huo K-G, Richer C, Fraulob-Aquino JC, Briet M, Lipman M, Sinnett D, Paradis P, Schiffrin EL. Distinct transcriptomic profile of small arteries of hypertensive patients with chronic kidney disease allows identifying miR-338-3p that targets GPX3 and PTPRS. J Hypertens. 2022;40:1394–1405. DOI:10.1097/HJH.0000000000003160. PMID 35703228.
309. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2022;35(5): 377–379. doi:10.1093/ajh/hpac031.
310. Schiffrin EL. From the Editor-in-Chief: Issue at a glance. Amer J Hypertens. 2022;35(6): 481–482. doi:10.1093/ajh/hpac044.
311. Comeau KD, Shokoples BG, Schiffrin EL. Sex Differences in the Immune System in Relation to Hypertension and Vascular Disease. Can J Cardiol. 2022;38(12):1828-1843. doi: 10.1016/j.cjca.2022.05.010. PMID: 35597532
312. Shokoples BG, Comeau K, Higaki A, Ferreira NS, Caillon A, Berillo O, Oukka M, Paradis P, Schiffrin EL. Angiotensin II induced a steeper blood pressure elevation in IL-23 receptor-deficient mice: Role of interferon-γ-producing T cells. Hypertension Res. 2023; 46(1):40-49. doi: 10.1038/s41440-022-01055-3. Epub 2022 Oct 15. PMID: 36241706
313. Yang H, Wang Y, Tang MC, Waters P, Wang S, Allard P, Ryan RO, Nuyt AM, Paradis P, Schiffrin EL, Furtos A, Mitchell GA. Cardiac-specific deficiency of 3-hydroxy-3-methylglutaryl coenzyme A lyase in mice causes cardiomyopathy and a distinct pattern of acyl-coenzyme A-related biomarkers. Mol Genet Metab. 2022 Sep 30;137(3):257-264. doi: 10.1016/j.ymgme.2022.09.008. Online ahead of print. PMID: 36228350.
314. Schiffrin EL. Mineralocorticoid receptor on T cells contributes to injury and remodeling of ischemic myocardium. Invited Editorial. Can J Cardiol. 2023. In press.
315. Schiffrin EL, Engert JC. Hypertension, brain imaging phenotypes and cognitive impairment: lessons from Mendelian randomisation. Invited Editorial. Eur Heart J. 2023.
316. Comeau K, Caillon A, Paradis P, Schiffrin EL. Determination of Interleukin-17A and Interferon- Production in γδ, CD4+, and CD8+ T Cells Isolated from Murine Lymphoid Organs, Perivascular Adipose Tissue, Kidney, and Lung. BioProtocol in press 2023.